Showing 5591-5600 of 5838 results for "".
- New School Initiative for Skin Cancer Preventionhttps://practicaldermatology.com/news/20120515-new_school_initiative_for_skin_cancer_prevention/2459798/La Roche-Posay recently collaborated with the Women's Dermatologic Society to launch “Time Out, Protect Your Skin” (TOPS) in schools to educate children and families about skin cancer prevention. New York City's Grace Church School was the first s
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- Celotres Earns CE Mark Approval for Wound Healinghttps://practicaldermatology.com/news/20120504-celotres_earns_ce_mark_approval_for_wound_healing/2459808/European regulators have granted CE Mark approval for Celotres™ hydrogel scaffold from Halscion, Inc. The CE Mark approval was based on the results of a prospective, multi-center, randomized, same-patient controlled, European clinical trial evaluati
- PhotoMedex Completes Sale of Common Stock for $40 Millionhttps://practicaldermatology.com/news/20120430-photomedex_completes_sale_of_common_stock_for_40_million/2459812/PhotoMedex, Inc. (NasdaqGS: PHMD) expects gross proceeds of $40 million, before deducting underwriting discounts, commissions and other offering expenses, from recent sale of shares of common stock. The company closed concurrent registered offerin
- Promiseb Complete Launches for Seborrheic Dermatitishttps://practicaldermatology.com/news/20120425-promiseb_complete_launches_for_seborrheic_dermatitis/2459814/Promiseb Complete, a new regimen for patients with seborrheic dermatitis (SD), is now available from Promius Pharma, LLC, an affiliate of Dr. Reddy's Laboratories,. The line features Promiseb Topical Cream, a non-steroidal, prescription cream fo
- Enrollments Complete for Two Phase 2 ALA-PDT AK Trialshttps://practicaldermatology.com/news/20120424-enrollments_complete_for_two_phase_2_ala-pdt_ak_trials/2459815/DUSA Pharmaceuticals (NASDAQ GM: DUSA) completed patient enrollment in its Phase 2 clinical trial studying the broad area application with 1-, 2-, and 3-hour drug incubation for the treatment of actinic keratoses (AKs) of the face or scalp
- DocBookMD App Offers Secure Communication, HIPAA Compliancehttps://practicaldermatology.com/news/20120424-docbookmd_app_offers_secure_communication_hipaa_compliance/2459816/Doctors can now send X-rays and lab results back and forth, securely and with full HIPAA compliance via a new application, available for iPhone, iPad, and Android. The DocBookMD app is free for doctors who are members of their state or county medical society. All activity is run through a secure ser
- Lasers May Treat Burn Scars of Military, Civilianshttps://practicaldermatology.com/news/20120420-lasers_may_treat_burn_scars_of_military_civilians/2459817/Fractional laser procedures may offer a treatment option for the estimated 1 million American who survive serious burn injuries each year, according to experts presenting at the ASLMS Annual Meeting in Kissimmee, FL. According to Jill Waibel, MD, credited with performing one of (or pe
- Amgen, Pfizer Will No Longer Co-Market Enbrelhttps://practicaldermatology.com/news/20120419-amgen_pfizer_will_no_longer_co-market_enbrel/2459819/Amgen and Pfizer will end co-promotion of Enbrel (etanercept) in North America this summer, the companies tell the Wall Street Journal. Amgen will assume full marketing responsibilities in the US, effective July 23.
- Slight Uptick for Biologics Predicted in EUhttps://practicaldermatology.com/news/20120419-slight_uptick_for_biologics_predicted_in_eu/2459820/In a recent TreatmentTrends© study with EU5 dermatologists, BioTrends Research Group, LLC finds that there has been a slight increase in the use of biologics in all of the EU5 countries except Italy, where usage has remained constant. Future prescribing habits will see moderate increases in prescrib